All News

Prescription medications and other health care items, including vitamins and supplements, eyewear, and natural medicine, such as pharmaceutical-grade CBD oil, is being delivered in the Dallas-Fort Worth (DFW) area with service to homes and offices.

Ramucirumab (Cyramza) in combination with erlotinib delayed disease progression in previously untreated patients with EGFR-mutated non-small cell lung cancer.

California has passed SB 159, becoming the first state allowing pharmacists to dispense HIV prevention pills to patients without a doctor’s prescription. Supporters say the legislation will greatly reduce the spread of infection.1

A webinar held by Trellis Rx discussed actionable ways to establish a successful clinic-based specialty pharmacy approach.

Top news of the day from across the health care landscape.

Nella Brisk, PharmD, knew she wanted to be a pharmacist, since the end of her high school career. Although she was aware of the amount of school and debt that would trail behind her, she was interested in starting her journey in the health care industry.

Understanding which molecules HIV needs in order to leave a cell and multiply is a crucial prerequisite for investigating how the spread can be prevented.

Erythropoietic protoporphyria is a rare metabolic disorder where exposure to light may be extremely painful for affected individuals.

Wilate, a von Willebrand factor replacement therapy, was approved for use in patients with hemophilia A for routine prophylaxis and on demand treatment and control of bleeding episodes.

The National Association of Specialty Pharmacy's annual meeting is one of the industry’s only conferences where all stakeholders can fully participate.

NAMI Basics OnDemand is an adaptation of the in-person NAMI Basics, a free, 6-session education program for parents, caregivers, and other family who provide care for adolescents aged 22 years or younger who are experiencing mental health symptoms.

TIN Rx is aiming to serve the most vulnerable populations, including LGBTQ patients, homeless patients, and others who may typically face stigma in pharmacies.

Brolucizumab is the most clinically advanced humanized single-chain antibody fragment. This type of antibody is highly sought after due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics.

Top news of the day from across the health care landscape.

Trifarotene is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin. The cream is also the first topical treatment specifically studied and proven to treat both facial (forehead, cheeks, nose, and chin) and truncal (chest, shoulders, and back).

Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.

The new drug application for PF708 was submitted under the 505(b)(2) regulatory pathway with teriparatide injection as the reference drug.

The keynote, Priming Pharmacists for Making an Impact in Oncology Value-Based Care, sets the stage for the entire conference and highlights how pharmacists are critical to the multidisciplinary team in providing value in patient-centered oncology care.

Ron Lanton III, Esq., discusses the Prescription Drug Price Relief Act of 2019 at the National Association of Specialty Pharmacists Annual Meeting at Washington, DC.

Top news of the day from across the health care landscape.

The study aimed to determine the association between antidepressant classes, types, and duration of use during pregnancy and the risk of gestational diabetes.

A new study by Prime Therapeutics LLC has shown a sharp increase in the number of drug "super spenders," defined by the researchers as members with pharmacy and medical drug therapy claims of $250,000 or more annually.

Ixekizumab showed superiority versus guselkumab in the treatment of moderate to severe plaque psoriasis.

Subcutaneous immunoglobin has increased treatment options for patients with several conditions, such as primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy.

A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.

Benralizumab is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid depletion of eosinophils via programmed cell death.

The PARP inhibitor received a Breakthrough Therapy Designation for metastatic castration-resistant prostate cancer based on data released from the GALAHAD study.

Top news of the day from across the health care landscape.